NCI’s Consumer Liaison Group Chooses Four Areas of Concern

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

The co-chairs are M. Venus Gines, a breast-cancer survivor from Lithonia, Ga, active in community work with the American Cancer Society; Susan A. Leigh of Tucson, Ariz, a survivor of Hodgkin’s disease, breast cancer, and bladder cancer, and active in the National Coalition for Cancer Survivorship and the Oncology Nursing Society; and Daniel M. Moore, Jr., a prostate cancer survivor from Decatur, Ill, who started the Central Illinois US TOO! prostate cancer support group.

The consumer group’s four areas of immediate concern are communications and immediate access to reliable cancer information; informed consent, including making forms more understandable; patient consumer issues and population and genetics studies; and ways to identify additional consumer representatives for NCI committees and groups.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.